KMT2A and neoplasm: Using the same dose of daunorubicin (5 mg/kg) as with ABT-737, combination therapy with ABT-199 was more efficacious than treatment with daunorubicin alone, for tumours of both genotypes (Fig. 8b; p < 0.001 for WT/MLL-AF9 AMLs, p < 0.05 for BCL-2tg/MLL-AF9 AMLs), although all treated mice still died within 30 days.